Therefore, the loss of EZH2-mediated inhibition of BCAT1 expression may contribute to altered metabolic profiles in MPN-driving cells, which may explain the poor prognosis of MPN patients who harbor EZH2 mutations (60). Here, EZH2 is linked to myeloproliferative neoplasm.